Effect of selenium supplementation on cardiometabolic risk factors in polycystic ovary syndrome (PCOS) patients: A systematic review and meta-analysis of randomized clinical trials

IF 2.4 Q3 NUTRITION & DIETETICS
Ahmed Abu-Zaid , Ibtihal Abdulaziz Bukhari , Abdullah Alyousef , Saeed Baradwan , Naif Bin Muaythir , Yasir Almudaymigh , Mohammed Abuzaid , Saleh A.K. Saleh , Heba M. Adly , Osama Alomar
{"title":"Effect of selenium supplementation on cardiometabolic risk factors in polycystic ovary syndrome (PCOS) patients: A systematic review and meta-analysis of randomized clinical trials","authors":"Ahmed Abu-Zaid ,&nbsp;Ibtihal Abdulaziz Bukhari ,&nbsp;Abdullah Alyousef ,&nbsp;Saeed Baradwan ,&nbsp;Naif Bin Muaythir ,&nbsp;Yasir Almudaymigh ,&nbsp;Mohammed Abuzaid ,&nbsp;Saleh A.K. Saleh ,&nbsp;Heba M. Adly ,&nbsp;Osama Alomar","doi":"10.1016/j.phanu.2023.100358","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span><span>Polycystic ovary syndrome<span> (PCOS) has been shown to be associated with cardiometabolic risk factors. Selenium (Se) is a naturally occurring mineral trace element that constitutes an essential component of selenoproteins and plays a vital role in antioxidant defense. This </span></span>systematic review and meta-analysis aims to assess the effects of selenium supplementation on cardiometabolic risk factors </span>in patients with PCOS.</p></div><div><h3>Methods</h3><p>MEDLINE, Cochrane Central Register of Controlled Trials<span>, Web of Science, and Scopus<span> databases were searched up to March 2023 for randomized clinical trials that evaluated the effect of oral selenium supplementation on patients with PCOS. We employed a random-effects model to generate pooled estimates and 95% confidence intervals (CI).</span></span></p></div><div><h3>Results</h3><p><span>Seven trials published between 2015 and 2022 were included. All the included studies were double blind, placebo-controlled trials. Selenium supplementation resulted in a significant decrease in VLDL<span><span><span> (SMD = −0.35, 95% CI: −0.65; −0.05), MDA (SMD = −0.89, 95% CI: −1.21; −0.57) and hs-CRP (SMD = −0.38, 95% CI: −0.73; −0.03), as well as a significant increase in </span>QUICKI (SMD = 0.78, 95% CI: 0.47; 1.09). The current meta-analysis did not find any significant changes in </span>FPG, insulin, HOMA-IR, </span></span>TC<span><span>, TG<span>, HDL, </span></span>LDL<span><span><span>, TAC, GSH, </span>NO, </span>SHBG<span>, total testosterone, or mFG score for PCOS patients following selenium supplementation compared to placebo.</span></span></span></p></div><div><h3>Conclusion</h3><p><span><span>Selenium supplementation may serve as a good adjunct therapy in patients with PCOS to decrease lipid peroxidation and inflammatory status. Moreover, selenium may improve </span>insulin sensitivity in these patients. However, the overall effects of selenium on all cardiometabolic risk factors in PCOS patients still need to be evaluated through large population and long duration </span>RCTs.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmaNutrition","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213434423000300","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Polycystic ovary syndrome (PCOS) has been shown to be associated with cardiometabolic risk factors. Selenium (Se) is a naturally occurring mineral trace element that constitutes an essential component of selenoproteins and plays a vital role in antioxidant defense. This systematic review and meta-analysis aims to assess the effects of selenium supplementation on cardiometabolic risk factors in patients with PCOS.

Methods

MEDLINE, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus databases were searched up to March 2023 for randomized clinical trials that evaluated the effect of oral selenium supplementation on patients with PCOS. We employed a random-effects model to generate pooled estimates and 95% confidence intervals (CI).

Results

Seven trials published between 2015 and 2022 were included. All the included studies were double blind, placebo-controlled trials. Selenium supplementation resulted in a significant decrease in VLDL (SMD = −0.35, 95% CI: −0.65; −0.05), MDA (SMD = −0.89, 95% CI: −1.21; −0.57) and hs-CRP (SMD = −0.38, 95% CI: −0.73; −0.03), as well as a significant increase in QUICKI (SMD = 0.78, 95% CI: 0.47; 1.09). The current meta-analysis did not find any significant changes in FPG, insulin, HOMA-IR, TC, TG, HDL, LDL, TAC, GSH, NO, SHBG, total testosterone, or mFG score for PCOS patients following selenium supplementation compared to placebo.

Conclusion

Selenium supplementation may serve as a good adjunct therapy in patients with PCOS to decrease lipid peroxidation and inflammatory status. Moreover, selenium may improve insulin sensitivity in these patients. However, the overall effects of selenium on all cardiometabolic risk factors in PCOS patients still need to be evaluated through large population and long duration RCTs.

补充硒对多囊卵巢综合征(PCOS)患者心脏代谢危险因素的影响:随机临床试验的系统综述和荟萃分析
背景多囊卵巢综合征(PCOS)已被证明与心脏代谢危险因素有关。硒(Se)是一种天然存在的矿物微量元素,是硒蛋白的重要成分,在抗氧化防御中起着至关重要的作用。本系统综述和荟萃分析旨在评估补充硒对多囊卵巢综合征患者心脏代谢危险因素的影响。方法检索截至2023年3月的MEDLINE、Cochrane Central Register of Controlled Trials、Web of Science和Scopus数据库,以进行随机临床试验,评估口服硒补充剂对多囊卵巢综合征患者的影响。我们采用了随机效应模型来生成汇总估计和95%置信区间(CI)。结果纳入了2015年至2022年间发表的7项试验。所有纳入的研究均为双盲安慰剂对照试验。补硒可显著降低极低密度脂蛋白(SMD=-0.35,95%CI:−0.65;−0.05)、丙二醛(SMD=−0.89,95%CI:−1.21;−0.57,与安慰剂相比,补充硒后多囊卵巢综合征患者的GSH、NO、SHBG、总睾酮或mFG评分。结论补充硒对PCOS患者有较好的辅助治疗作用,可降低脂质过氧化和炎症状态。此外,硒可以改善这些患者的胰岛素敏感性。然而,硒对多囊卵巢综合征患者所有心脏代谢危险因素的总体影响仍需通过大量人群和长期随机对照试验进行评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
PharmaNutrition
PharmaNutrition Agricultural and Biological Sciences-Food Science
CiteScore
5.70
自引率
3.10%
发文量
33
审稿时长
12 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信